ACADIA Pharmaceuticals Inc. (ACAD) Stock Overview
Explore ACADIA Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
ACADIA Pharmaceuticals Inc. (ACAD)
Key Financials
Key Financials
Market Cap
4.4B
P/E Ratio
11.44
EPS (TTM)
$2.04
ROE
0.36%
ACAD Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of ACADIA Pharmaceuticals Inc. (ACAD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 66.90, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $25.93.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 11.44 and a market capitalization of 4.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.